Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business, Opella, to the US private equity firm Clayton, Dubilier & Rice (CD&R). Opella ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Sanofi, France's biggest pharmaceutical group, said last week that it was in talks with CD&R for the sale of a 50% controlling stake in Opella, triggering criticism from government opponents over the ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... rising income levels and greater health and well-being awareness, Sanofi ...

Sanofi and CD&R enter exclusive talks to sell a 50% stake in Opella, Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra ...

PAI Partners increased its offer for Sanofi’s consumer health division by 200 million euros. CD&R remains the frontrunner for a 50% stake in Sanofi’s Opella, despite PAI's late bid.

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

Sanofi could announce the deal with buyout firm CD&R as soon as early next week, according to the people. The consumer health unit, known as Opella, is set to be valued at around €15 billion ...

(Bloomberg) -- Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail ...